Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Letters in Response to Previous Publication
ARTICLE IN PRESS
doi:
10.25259/IJDVL_539_2021

A combination of trimethoprim/sulfamethoxazole with linezolid is useful for actinomycotic mycetoma: A summary of the existing data and the rationale of combination therapy

Department of Dermatology, Venereology and Leprosy, Dr. Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi, India
Corresponding author: Dr. Kabir Sardana, Department of Dermatology, Venereology and Leprosy, Dr. Ram Manohar Lohia Hospital and Atal Bihari Vajpayee Institute of Medical Sciences, New Delhi, India. article.sardana@gmail.com
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Sardana K, Sachdeva S. A combination of trimethoprim/sulfamethoxazole with linezolid is useful for actinomycotic mycetoma: A summary of the existing data and the rationale of combination therapy. Indian J Dermatol Venereol Leprol, doi: 10.25259/IJDVL_539_2021

Sir,

We read with interest the case by Patra et al.1 and would like to highlight the dosing that we had used predating this case.2 We would like to dwell on the laid down principles that dictate usage of antibiotics to effect clinical cure in actinomycotic mycetoma.

Antibiotic dosages are determined using susceptibility data, pharmacodynamics and treatment outcomes. Important considerations before instituting treatment include: (1) Region to region variation of antibiotic susceptibility patterns that are constantly changing; (2) the concentration of antibiotic attained at the site of infection over a dosing interval of 24 hours; (3) mechanism of antibacterial action of antibiotics; (4) the likelihood of the dose producing a microbiological as well as clinical cure; (5) the adverse effects that occur; and, (6) the probability of development of antimicrobial resistance. Pharmacodynamic descriptions provide the clinician with information on how the bacterial pathogens are killed. These parameters include%T>MIC, AUC: MIC or Cmax: MIC, where T is time, MIC is minimum inhibitory concentration, AUC is area under curve and Cmax is the maximum concentration. These parameters help to achieve the “antibiotic exposure break point” that can enable a proper dosage schedule. In the absence of this, guidance provided by the “break point organizations” such as the United States Committee on Antimicrobial Susceptibility Testing (www. uscast.org) or the Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing (https://clsi.org/education/microbiology/ast) can be used.

In our cases,2 we confirmed Nocardia by culture and used existing microbiological data gleaned from the prevalent worldwide data, using the laid down principles of therapy. We found the need to synergise the use of trimethoprim-sulfametoxazole (TMP/SMX) and linezolid as the existing data in this condition relied on at least two drugs. Our data showed that a regimen of linezolid 600 mg twice a day for three months along with TMP/ SMX (sulfamethoxazole 1200 mg and trimethoprim 240 mg) for six months led to remission in three out of four cases.2 Mean time in which the lesion healed was three months. Previously, Welsch et al.3 and Epelboin et al.4 have also reported use of linezolid in the specific management of actinomycotic mycetoma.

Here it is pertinent to note that we felt the need to combine these two drugs but in the case by Patra et al.,1 we did not note any data on culture or antibiogram. While authors administered monotherapy, this may not have been justified unless resistance had been documented to all the previously used drugs. We fear a single drug may predispose the patient to resistance and recurrence.

There are three general settings, elaborated as follows, in which combination antimicrobial therapy is known to be advantageous. The first is in the empirical setting, when treating an infection for which the potential etiologic microbial species are sufficiently broad so that one agent is unlikely to cover all of them. The second is for preventing the emergence of resistance in specific clinical settings. The third is a rare circumstance in which two active agents are known to result in superior clinical outcomes compared with a single active agent against a susceptible organism.5

In actinomycotic mycetoma, when the correct species is not identified, it makes logical sense to combine two classes of drugs. It has been our experience that using TMP/SPX with linezolid is effective with long term results obviating the risk of resistance. Also, long-term linezolid can lead to haematological side effects which need monitoring, which was not mentioned in the report by Patra et al.1

There is an additional advantage of using two oral drugs; it obviates the need for parenteral administration of aminoglycosides. But any such use should be based on an antibiogram. Drug monotherapy should not be the preferred line of treatment, according to the existing principles of antibiotic use.5

References

  1. , , , , . Linezolid: A novel treatment option for the treatment of a non-responsive case of actinomycotic mycetoma. Indian J Dermatol Venereol Leprol. 2021;87:455.
    [CrossRef] [PubMed] [Google Scholar]
  2. , . Newer therapeutic modalities for Actinomycetoma by Nocardia species. Int J Dermatol. 2018;57:e64-5.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , . Disseminated actinomycetoma due to Nocardia wallacei. Int J Dermatol. 2018;57:580-2.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , , et al. Actinomycétome du genou à Nocardia otitidiscaviarum aux Comores [Actinomycetoma of the knee due to Nocardia otitidiscaviarum described in the Comoro Islands] Ann Dermatol Venereol. 2013;140:287-90.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
2,164

PDF downloads
53
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections